BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10202439)

  • 1. [Proteases and protease inhibitors in the treatment of cancer].
    Brünner NA
    Ugeskr Laeger; 1999 Mar; 161(11):1577-80. PubMed ID: 10202439
    [No Abstract]   [Full Text] [Related]  

  • 2. [Proteases in malignant tumors. Their significance for pathogenesis and possible therapeutic consequences].
    Fröhlich E
    Dtsch Med Wochenschr; 2004 Feb; 129(8):391-5. PubMed ID: 14961448
    [No Abstract]   [Full Text] [Related]  

  • 3. Suicidal tumor proteases.
    Sloane BF
    Nat Biotechnol; 1996 Jul; 14(7):826-7. PubMed ID: 9631001
    [No Abstract]   [Full Text] [Related]  

  • 4. Extracellular proteases as targets for treatment of cancer metastases.
    Lee M; Fridman R; Mobashery S
    Chem Soc Rev; 2004 Sep; 33(7):401-9. PubMed ID: 15354221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological activity and clinical implications of the matrix metalloproteinases.
    Rydlova M; Holubec L; Ludvikova M; Kalfert D; Franekova J; Povysil C; Ludvikova M
    Anticancer Res; 2008; 28(2B):1389-97. PubMed ID: 18505085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease inhibitors: a panacea?
    Haq SK; Rabbani G; Ahmad E; Atif SM; Khan RH
    J Biochem Mol Toxicol; 2010; 24(4):270-7. PubMed ID: 20135636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease inhibitors: role and potential therapeutic use in human cancer.
    DeClerck YA; Imren S
    Eur J Cancer; 1994; 30A(14):2170-80. PubMed ID: 7857719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of tissue kallikrein inhibitors: importance in cancer.
    Bhoola KD; Misso NL; Naran A; Thompson PJ
    Curr Opin Investig Drugs; 2007 Jun; 8(6):462-8. PubMed ID: 17621876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and clinical studies of MMP inhibitors in cancer.
    Drummond AH; Beckett P; Brown PD; Bone EA; Davidson AH; Galloway WA; Gearing AJ; Huxley P; Laber D; McCourt M; Whittaker M; Wood LM; Wright A
    Ann N Y Acad Sci; 1999 Jun; 878():228-35. PubMed ID: 10415734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of protease and protease inhibitors in cancer pathogenesis and treatment.
    Eatemadi A; Aiyelabegan HT; Negahdari B; Mazlomi MA; Daraee H; Daraee N; Eatemadi R; Sadroddiny E
    Biomed Pharmacother; 2017 Feb; 86():221-231. PubMed ID: 28006747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proteasome inhibitors--new option in the treatment of tumor diseases].
    Spicka I; Klener P
    Cas Lek Cesk; 2004; 143(10):701-4. PubMed ID: 15584622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase inhibitors as anticancer agents.
    Konstantinopoulos PA; Karamouzis MV; Papatsoris AG; Papavassiliou AG
    Int J Biochem Cell Biol; 2008; 40(6-7):1156-68. PubMed ID: 18164645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiproteases in the pathogenesis of neoplastic diseases].
    Dabrowska M
    Przegl Lek; 1998; 55(9):475-9. PubMed ID: 10085727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologists take degrading route to tackle cancer.
    Abbott A
    Nature; 2004 Jun; 429(6994):794. PubMed ID: 15215827
    [No Abstract]   [Full Text] [Related]  

  • 15. Proteinase inhibitors in malignancy: therapeutic promise or another white elephant?
    Dodwell DJ
    J R Soc Med; 1993 Oct; 86(10):573-6. PubMed ID: 8230059
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
    Levitt NC; Eskens FA; O'Byrne KJ; Propper DJ; Denis LJ; Owen SJ; Choi L; Foekens JA; Wilner S; Wood JM; Nakajima M; Talbot DC; Steward WP; Harris AL; Verweij J
    Clin Cancer Res; 2001 Jul; 7(7):1912-22. PubMed ID: 11448904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteases and protease inhibitors in cancer.
    Van Noorden CJ
    Acta Histochem; 1998 Nov; 100(4):344-54. PubMed ID: 9842415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteinase inhibition in invasive cancer therapy: four control levels of matrix degradation.
    Opdenakker G; Paemen L; Norga K; Masure S
    Int J Cancer; 1997 Mar; 70(5):628-30. PubMed ID: 9052766
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II trial of marimastat in advanced pancreatic cancer.
    Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP
    Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmembrane proteases as disease markers and targets for therapy.
    Antczak C; De Meester I; Bauvois B
    J Biol Regul Homeost Agents; 2001; 15(2):130-9. PubMed ID: 11501970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.